2020 Nobel Prize in Physiology or Medicine: Alter, Houghton, and Rice, Unveiling the Hepatitis C Virus

What You'll Learn from This Article

The 2020 Nobel Prize in Physiology or Medicine was awarded to three individuals who definitively identified the causative virus of hepatitis C, a mysterious form of chronic hepatitis that emerged after blood transfusions in the late 20th century. At the U.S. NIH, Harvey Alter demonstrated through chimpanzee experiments in the 1970s that the disease was caused by a new pathogen, distinct from hepatitis A and B. At the University of Alberta in Canada, Michael Houghton in 1989 obtained the first complete genome sequence of the HCV (Hepatitis C Virus) through direct molecular cloning from infected blood, without relying on tissue culture. At the Rockefeller University in the U.S., Charles Rice created a fully infectious HCV clone, thereby conclusively establishing that this virus was the causative agent, fulfilling Koch's postulates. The combination of these three discoveries fundamentally changed global blood transfusion safety, and in the early 21st century, the emergence of direct-acting antiviral agents (DAAs) such as Sofosbuvir made hepatitis C a curable disease.

Beyond Common Knowledge: A Pathogen That Remained Hidden for 30 Years Because It Couldn't Grow in a Test Tube

The common understanding that "viruses are grown in cell culture to identify them" was the standard in the 20th century. Following Koch's postulates, most pathogens were isolated and cultured in the laboratory to confirm their identity. However, in the case of the hepatitis C virus, this standard approach failed for over 30 years. The virus only grew under specific tissue culture conditions, and no attempts at cultivation were successful. The pathogen clearly existed, but it remained elusive.

Framed within a CS perspective, this was a challenge of reverse-engineering a black box where only the executable file is observable without the source code. Alter confirmed through behavioral observation (side-channel analysis) that this executable existed and caused infection. Houghton created a memory dump from infected chimpanzee blood and extracted the payload sequence. Rice recompiled the extracted sequence and demonstrated that it could actually be executed. It was only through the combination of these three steps that the identity of the pathogen was definitively confirmed.

The uniqueness of this story lies in its methodology. To deal with a pathogen that could not be grown in tissue culture, Houghton pushed the limits of molecular cloning, a new technology that emerged in the late 20th century, and this approach became a standard method for discovering other non-cultivable viruses.

A Snapshot of the Times: The First Year of the Pandemic, a World of Masks and Lockdowns

2020 was the year that humanity faced its first major pandemic of the 21st century. The novel coronavirus, which emerged in Wuhan in January and spread globally, led to the WHO declaring COVID-19 a pandemic on March 11. Lockdowns, mask shortages, border closures, the collapse of hospital emergency rooms, and disparities in national responses—all of this tested the international community in unprecedented ways. The rapid development of mRNA vaccines began, and in December, the first vaccines received emergency use authorization, marking a turning point.

South Korea achieved relative success in its initial response under the banner of "K-Quarantine." While it experienced mask shortages between January and April, it stabilized the situation with a public mask distribution system, and its combination of contact tracing and expanded testing gained international attention. In the April 15 general election, the ruling Democratic Party secured 180 seats, a landslide victory that was interpreted as a political success for K-Quarantine. However, the year marked the beginning of online classes in schools, leading to increased learning loss and social inequality.

Globally, the death of George Floyd in Minneapolis on May 25 sparked the Black Lives Matter (BLM) movement, which spread across the world. Large-scale protests for racial justice spread beyond the United States to Europe and Asia. In the U.S. presidential election on November 3, Biden defeated Trump, but Trump's refusal to accept the results led to the January 6 attack on the Capitol the following year.

In the tech world, SpaceX's Crew Dragon successfully launched a manned mission on May 30, ushering in the era of private space companies conducting manned missions. In September, BTS's "Dynamite" topped the Billboard Hot 100, marking the first time a K-pop group had reached the top of the charts.

In the scientific community, this award was a symbolic recognition in the era of the pandemic. Hepatitis C had plagued humanity for 30 years, and the culmination of this story—the emergence of curable DAAs—was a prime example of successful strategies for combating chronic infectious diseases in the late 20th century. In the face of the new threat of COVID-19, this success story served as a beacon of hope. It reinforced the optimistic belief that once a virus is discovered, a cure will eventually be found. This optimism was confirmed the following year with the decisive success of mRNA vaccine development.

A Narrative of Individuals: Three Decades, Three Steps, and the Complete Identification of a Pathogen

Harvey Alter (1935– ) was born in New York City and received his M.D. from the University of Rochester, after which he joined the NIH Clinical Center. During his time, blood transfusions were rapidly expanding in clinical practice, and along with this, post-transfusion hepatitis emerged as a serious adverse effect. Hepatitis A (transmitted orally, acute recovery) and hepatitis B (bloodborne, potential for chronic infection) were already known, but a significant portion of post-transfusion hepatitis was suspected to be caused by a new pathogen unrelated to these two types.

Alter's crucial experiment was the transmission of infection to chimpanzees. He demonstrated that chimpanzees developed similar hepatitis when injected with the blood of patients with post-transfusion hepatitis, and that the infectivity of this blood was maintained even after being neutralized with A- and B-type antibodies. This was strong evidence of the existence of a new pathogen, which he named non-A non-B hepatitis. The problem was that the identity of this pathogen remained elusive, and no laboratory was able to successfully culture it.

Michael Houghton (1949– ), born in the United Kingdom, later emigrated to Canada. He led his own research team at Chiron, a biotechnology company in California. His approach was bold and innovative. In the absence of tissue culture, he attempted to create a cDNA library from infected chimpanzee blood and extract the sequence. This was an extreme application of molecular cloning, a technology that had been newly established at the time, and after several years of failure, he succeeded in 1989.

The key screening trick was to screen the recombinant proteins created from this cDNA library with serum from infected patients. Since the patient's serum would contain antibodies against pathogen proteins, identifying the recombinant protein to which the antibodies bind would indicate that the cDNA encoding that protein was a fragment of the viral genome. Using this method, Houghton's team announced in a 1989 Science paper that they had obtained the first fragment of the HCV genome, and the complete genome sequence was subsequently completed. It was the first viral genome to be identified solely through cloning, without direct observation.

Charles Rice (1952– ), born in Sacramento, California, received his B.S. from UC Davis and his Ph.D. from Caltech, after which he established his own laboratory at the University of Washington and later at the Rockefeller University. His challenge was the final step: "Is the genomic sequence found by Houghton actually infectious? Is there definitive proof that this virus actually causes the disease?"

Rice's team spent several years trying to create an infectious HCV clone—a form of HCV genome RNA that could be reconstituted in the laboratory and actually cause infection. They injected chimpanzees with various combinations of HCV genome fragments, but most attempts failed to cause infection. Finally, they discovered that a specific sequence in the 3' UTR was essential for infectivity, and they created a complete infectious clone that included this sequence. When this clone was injected into chimpanzees, it caused a normal HCV infection, thereby completing the final proof that "this genomic sequence is indeed the pathogen," fulfilling Koch's postulates.

These three steps were completed over 30 years. Alter's demonstration of the existence of the pathogen (1970s), Houghton's acquisition of the genome sequence (1989), and Rice's infectious clone (late 1990s). The Nobel Prize recognized all three of these steps, and it became a model for the complete identification of a virus.

Key Achievements: Black Box Reverse Engineering Seen Through a CS Lens

The pipeline for the discovery of the hepatitis C virus can be depicted as follows:

• Step 1 (Alter, Side-Channel Observation): In cases of hepatitis occurring after blood transfusions, A- and B-type pathogens were ruled out, and the existence of a remaining causative agent was demonstrated through the transmission of infection to chimpanzees. Although the identity of the pathogen was unknown, evidence of its presence and activity was established.
• Step 2 (Houghton, Payload Extraction from Memory Dump): Total RNA was extracted from infected chimpanzee blood → a cDNA library was constructed by reverse transcription → recombinant proteins were expressed → screened with serum from infected patients → fragments encoding pathogen proteins were identified → the remaining parts of the genome were expanded. The genome sequence was obtained solely through molecular cloning, without tissue culture.
• Step 3 (Rice, Infectious Clone Compilation): The obtained sequence was assembled to create a complete infectious clone → normal infection was reproduced by injecting it into chimpanzees → Koch's postulates were completed.

These three steps represent a standard method for pathogen discovery: "observation → genome acquisition → infectious reproduction." However, in the case of HCV, the methodological innovation of bypassing tissue culture in Step 2 was crucial. This approach became a standard method for discovering other non-cultivable pathogens.

HCV itself is an RNA virus belonging to the Flaviviridae family. Its genome is a single-stranded RNA of approximately 9600 nucleotides, with a single large open reading frame (ORF) that is translated into a polyprotein, which is then cleaved into several mature proteins. These mature proteins include NS3 (protease), NS5A (replication regulator), and NS5B (RNA polymerase), which became the targets of DAA-based antiviral agents.

The architecture of chronic infection after infection can be depicted as follows:

• Acute Infection: HCV infects hepatocytes and causes acute hepatitis. Approximately 20-30% of infected individuals recover naturally at this stage.
• Chronic Infection: The remaining 70-80% progress to chronic infection. HCV continuously replicates in hepatocytes, causing chronic hepatitis.
• Liver Fibrosis → Cirrhosis: Chronic inflammation leads to liver fibrosis and cirrhosis over 20-30 years.
• Hepatocellular Carcinoma: Some patients with cirrhosis develop hepatocellular carcinoma. HCV is one of the major causes of liver cancer worldwide.

The advent of DAAs completely reversed this architecture. Starting with Sofosbuvir (approved by the FDA in 2013), several combination therapies, including Harvoni (sofosbuvir + ledipasvir) and Epclusa (sofosbuvir + velpatasvir), were developed, and the current standard therapy achieves a cure rate of 95% or higher with 8-12 weeks of oral administration. This is one of the most dramatic success stories in the treatment of chronic infectious diseases in the 20th century, and the transition from the low efficacy and severe side effects of interferon therapy to curable oral therapies is the clinical culmination of this story.

However, it is important to acknowledge the limitations of this analogy. The fact that it took 30-50 years from the discovery of HCV to a cure reminds us that the discovery of a new infectious disease does not necessarily lead to a rapid cure. The rapid development of mRNA vaccines against COVID-19 was an exceptional success, and it was due to the accumulation of vaccine technology infrastructure since the late 20th century and the molecular biology-based discoveries following the Human Genome Project. The time interval between discovery and treatment varies greatly depending on the technology available at the time for each pathogen.

Why It Matters: Blood Transfusion Safety, the DAA Era, and Lessons from the Pandemic

First, it fundamentally changed global blood transfusion safety. After the discovery of HCV, the HCV antibody test was developed and became the standard for screening donated blood in the 1990s. Subsequently, the addition of nucleic acid testing (NAT) further enhanced safety, and today, HCV infections from blood transfusions have almost disappeared worldwide. This is a decisive case of safety improvement in transfusion medicine in the late 20th century.

Second, it brought about the possibility of complete cure in the DAA era. In the 20th century, pegylated interferon + ribavirin treatment had an efficacy of 40-50% and caused severe side effects. In the 21st century, DAA therapy involves 8-12 weeks of oral administration, a cure rate of over 95%, and minimal side effects. It is the first case of a chronic viral infection becoming a curable disease, and it has become a reference point for cure strategies for other chronic infectious diseases (such as hepatitis B and HIV).

Third, it supports the WHO's 2030 HCV elimination goal. In 2016, the WHO adopted a goal of eliminating hepatitis C as a public health threat by 2030. This aims to reduce new infections by 90% and deaths by 65% through continuous screening, early treatment, and infection prevention. Several countries are implementing national plans towards this goal, and some countries, such as Egypt and Georgia, have already made significant progress with large-scale national programs.

Fourth, it has become a standard for discovery methodology. The method used by Houghton – directly cloning from infected samples without tissue culture – has been used to discover several pathogens that cannot be cultured, and it has become the conceptual ancestor of today's metagenomics – a method of sequencing all genes in a sample to find pathogen genes. The fact that the genome of SARS-CoV-2, the virus that causes COVID-19, was obtained within a few weeks of its emergence was also due to this evolved form of the methodology.

Fifth, it serves as a reference point for crisis response in the pandemic era. The story of HCV demonstrates a 30-year gap between the discovery of a virus and the emergence of a treatment. The rapid development of vaccines for COVID-19 was an unusual event, and for most new infectious diseases, it takes a considerable amount of time from discovery to treatment. This provides a lesson that responding to infectious diseases requires not only the discovery itself but also ongoing research support and maintenance of clinical infrastructure.

Sixth, it has had a significant clinical impact in Korea. In the late 20th century, Korea had a relatively high prevalence of hepatitis B and hepatitis C. Hepatitis B has been significantly reduced through national vaccination, and hepatitis C has become curable with the introduction of DAAs. The National Health Insurance has included DAAs in its coverage since 2015, and since then, the number of patients with chronic hepatitis C has decreased significantly due to expanded national screening and access to treatment.

Seventh, it has cultural value as a complete story of pathogen discovery. The story of Alter, Houghton, and Rice demonstrates the ideal three-step process of pathogen discovery: demonstrating its existence, obtaining its genome, and reproducing its infectivity. This is a model for the methodology we should follow when encountering new pathogens in the future, and it has become a textbook reference in the pandemic era.

The story of a pathogen discovered after 30 years and a disease that became curable after 40 years was recognized with the Nobel Prize in the first year of the pandemic. The optimism that a treatment will eventually be found if a virus is discovered is conditional, but it is a proven fact, and the condition is continued research support and international cooperation. The 20th Nobel Prize in Physiology or Medicine of the new century was a moment that provided a basis for this optimism.

→ Previous: 2019 Nobel Prize in Physiology or Medicine → Next: 2021 Nobel Prize in Physiology or Medicine